State of Alaska Department of Revenue Sells 145 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
State of Alaska Department of Revenue reduced its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 1.3% ...
Deutsche Bank Aktiengesellschaft Initiates Coverage on Sarepta Therapeutics (NASDAQ:SRPT)
Equities research analysts at Deutsche Bank Aktiengesellschaft assumed coverage on shares of Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) in a research report issued on Tuesday, MarketBeat ...
Managed Healthcare Executive2d
Sarepta Announces Positive Results for Elevidys, Gene Therapy for Duchenne
Results show improved functional outcomes for people with Duchenne muscular dystrophy who are ambulatory. Elevidys, which is ...
Insider Monkey15d
Jim Cramer Says ‘I Think Sarepta Therapeutics, Inc. (SRPT) Is A Speculative Situation Where They Have Great Science’
In this article, we are going to take a look at where Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stands against the other stocks. Jim Cramer, the host of Mad Money, recently expressed his concerns ...
Business Insider17d
Sarepta told RBC patient death confirmed unrelated to Elevidys
Shares of Sarepta (SRPT) are down this morning, potentially due to the latest FDA Adverse Event Reporting System update on Elevidys, which included a patient death from November in a patient who ...
Pharmabiz18d
Roche announces positive results from EMBARK phase III study of Elevidys in ambulatory individuals with DMD
In 2019, Roche entered into a global collaboration agreement with Sarepta Therapeutics ... phase Ib study assessing Elevidys micro-dystrophin protein expression and safety of Elevidys in seven cohorts ...
Business Insider18d
Sarepta Therapeutics’ Strong Market Position and Elevidys’ Promising Prospects Drive Buy Rating
In a report released yesterday, Kostas Biliouris from BMO Capital maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), with a price target of $200.00. Kostas Biliouris has ...